Becton, Dickinson and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Becton, Dickinson and Company sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).
Becton, Dickinson and Company: 33 sponsored US clinical trials, 1 recruiting.
Becton, Dickinson and Company sponsors 33 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 28 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral Intavenous Catheter Stabilization, with 1 trials.
Top-decile sponsor footprint
Becton, Dickinson and Company ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
28 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
33 total, page 1 of 1
The Continuity Study
NCT07216573
BD SiteRite(TM) 9 Ultrasound System - Clinical Study
NCT06632509
BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study
NCT06632496
SMART TRENDS Study
NCT05957406
BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.
NCT05557422
BD Veritor™ At-Home and BD Veritor™ Professional
NCT05352581
BD MiniDraw™ Capillary System Clinical Equivalence Study
NCT05186311
Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer
NCT05035615
A 7 Day Adhesive Device Wear Study to Evaluate BD StatLock™ Devices
NCT04845906
Prospective Healthy Volunteer Study of the Securis™ Stabilization Device
NCT04841330
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
NCT05032339
Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer
NCT05032313
Efficiency, and Emergency Department Nurse Preference Between 2 Methods of Visualization: A Pilot Study
NCT04811430
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
NCT04090242
Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle
NCT03878745
Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles
NCT03878758
Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle
NCT03267264
Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation
NCT03224299
Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth
NCT03229759
Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples
NCT03020121
BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study
NCT02662842
Accuracy Evaluation of the BD FACS Presto System
NCT02396355
Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
NCT02267876
Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults
NCT02382536
Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens
NCT01944722
Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans
NCT01772550
Clinical Evaluation of BD NEXT Pen Needle
NCT01852136
Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units
NCT01334606
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
NCT01231984
Intended Use Study of the BD SurePath Plus™ Pap
NCT01234480
Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles
NCT00928057
A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces
NCT01093833
Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose
NCT00741390
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Becton, Dickinson and Company pipeline
1 recruiting of 33 indexed (3% open); 28 completed (85%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Peripheral Intavenous Catheter Stabilization (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Becton, Dickinson and Company: open-pipeline peers nationwide
Peers matched on 33 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Becton, Dickinson and Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 33 trials (± recruiting share)
- Aclaris Therapeutics · 33 trials · 3% recruiting
- Antonios Likourezos · 33 trials · 12% recruiting
- Baylor University · 33 trials · 15% recruiting
- Centocor · 33 trials · 0% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Sarepta Therapeutics · 3% recruiting · 33 trials
- National Center for Complementary and Integrative Health (NCCIH) · 3% recruiting · 203 trials
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
Related
What to do with this Becton, Dickinson and Company page
33 registered trials is a research-attention snapshot, not an endorsement of Becton, Dickinson and Company or any single study.
- 1 of Becton, Dickinson and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Peripheral Intavenous Catheter Stabilization is the condition Becton, Dickinson and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral Intavenous Catheter Stabilization trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Becton, Dickinson and Company pipeline card: 33 registered trials from official public datasets.Report a data error.